SC-45662
SC-45662 is a 5-lipoxygenase inhibitor. SC-45662 inhibits the response of monocytes to phytohemagglutinin (PHA). SC-45662 inhibits superoxide production in neutrophils. SC-45662 slows early changes in lung mechanics and pulmonary hypertension in a sheep model of impaired lung function. SC-45662 can be used in research on diseases of the immune system, respiratory system, etc.
For research use only. We do not sell to patients.
- CAS No.: 135133-84-5
- Formula: C20H32O4S
- Molecular Weight:368.53
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Protocols
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
Description
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| RBL-1 | IC50 |
3.7 μM
Compound: SC-45662
|
The compound was tested for inhibitory activity in rat RBL-1 cells
The compound was tested for inhibitory activity in rat RBL-1 cells
|
[PMID: 1635053] |
Chemical Information
-
CAS No. 135133-84-5
-
Molecular Weight 368.53
-
Formula C20H32O4S
-
SMILES
O=C(O)CO[C@@H](C)[C@H](SC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1)C
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Research Protocol for Cardiovascular Diseases
Cardiovascular disease can be modeled as maladaptive cardiac remodeling, where ischemic injury or pressure overload activates inflammatory signaling, fibroblast activation, extracellular-matrix deposition, cardiomyocyte hypertrophy, vascular remodeling, and progressive ventricular dysfunction. The TGF-β/SMAD axis is a central profibrotic pathway after myocardial injury and pressure overload, while innate immune and cytokine pathways regulate leukocyte recruitment, scar formation, and adverse remodeling. Key unresolved questions include which inflammatory signals are reparative versus harmful, when fibrosis is protective versus maladaptive, and whether pathway inhibition improves function without weakening necessary infarct healing or compensatory remodeling.
Purity & Documentation
References
[1]. Weir MR, et al. The immunosuppressive properties of enisoprost and a 5-lipoxygenase inhibitor (SC-45662). Transplantation. 1991 Dec;52(6):1053-7. [Content Brief]
[2]. Kocan GP, et al. Contrasting effects of two arachidonate 5-lipoxygenase inhibitors on formyl-methionyl-leucyl-phenylalanine (fMLP) and complement fragment 5a induced human neutrophil superoxide generation. Biochem Pharmacol. 1994 Mar 15;47(6):1029-37. [Content Brief]
[3]. Kuratomi Y,et al. Effect of a 5-lipoxygenase inhibitor on endotoxin-induced pulmonary dysfunction in awake sheep. J Appl Physiol (1985). 1993 Feb;74(2):596-605. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
SC-45662 Related Classifications
HY-19080 Related Classifications
Powered by Bioz